Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer

References

• BorgetICoroneCNocaudieMSick leave for follow-up control in thyroid cancer patients: comparison between stimulation with thyrogen and thyroid hormone withdrawalEur J Endocrinol200715653153817468188
   PubMed Web of Science ®Google Scholar
• KilfoyBAZhengTHolfordTRInternational patterns and trends in thyroid cancer incidence, 1973–2002Cancer Causes Control200920552553119016336
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology End Results ProgramSEER Stat Fact Sheets: Thyroid Cancer Available from: http://seer.cancer.gov/statfacts/html/thyro.htmlAccessed May 29, 2015
   Google Scholar
• DuntasLBiondiBShort-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequencesEur J Endocrinol2007156131917218721
   PubMed Web of Science ®Google Scholar
• AlmeidaJVartanianJKowalskiLClinical predictors of quality of life in patients with initial differentiated thyroid cancersArch Otolaryngol Head Neck Surg2009135434234619380354
   PubMedGoogle Scholar
• DuranteCHaddyNBaudinELong-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab2006912892289916684830
   PubMed Web of Science ®Google Scholar
• RahibLSmithBDAizenbergRRosenzweigABFleshmanJMMatrisianLMProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United StatesCancer Res201474112913292124840647
   PubMed Web of Science ®Google Scholar
• SchultzPStavaCVassilopoulou-SellinRHealth profiles and quality of life of 518 survivors of thyroid cancerHead Neck200325534935612692870
   PubMed Web of Science ®Google Scholar
• HoftijzerHHeemstraKCorssmitEvan der KlaauwARomijnJSmitJQuality of life in cured patients with differentiated thyroid carcinomaJ Clin Endocrinol Metab200893120020317956954
   PubMed Web of Science ®Google Scholar
• Botella-CarreteroJGalanJCaballeroCSanchoJEscobar-MorrealeHFQuality of life and psychometric functionality in patients with differentiated thyroid carcinomaEndocr Relat Cancer20031060161014713270
   PubMed Web of Science ®Google Scholar
• LeeJIKimSHTanAHDecreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in KoreaHealth Qual Life Outcomes2010810120840792
   PubMed Web of Science ®Google Scholar
• TanLNanLThumbooJSundramFTanLRhinological and Otological Society, IncHealth-related quality of life in thyroid cancer survivorsLaryngoscope200711750751017334313
   PubMed Web of Science ®Google Scholar
• PaciniFItoYLusterMPitoiaFRobinsonBWirthLRadioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directionsExpert Rev Endocrinol Metab201275541554
   PubMedGoogle Scholar
• ShermanSICytotoxic chemotherapy for differentiated thyroid carcinomaClin Oncol (R Coll Radiol)201022646446820452757
   PubMed Web of Science ®Google Scholar
• EMAEMA Public Summary of Opinion on Orphan Designation. Sorafenib Tosylate for the Treatment of Follicular Thyroid Cancer2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/11/WC500156178.pdfAccessed December 4, 2014
   Google Scholar
• FDA News ReleaseFDA Approves Nexavar to Treat Type of Thyroid Cancer2013 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htmAccessed November 18, 2014
   Google Scholar
• FDA News ReleaseFDA Approves Lenvima for a Type of Thyroid Cancer2015 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434288.htmAccessed March 17, 2015
   Google Scholar
• WirthLJConsiderations for initiating treatment in advanced thyroid cancerClin Adv Heamtol Oncol201412suppl 141921
   Google Scholar
• GallopKKerrCSimmonsSMcIverBCohenEEWA qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phasesQual Life Res201524232533825106505
   PubMed Web of Science ®Google Scholar
• MernaghPCampbellSDietleinMLusterMMazzaferriEWestonACost effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspectiveEur J Endocrinol200615540541416914594
   PubMed Web of Science ®Google Scholar
• MernaghPSuebwongpatASilverbergJWestonACost effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspectiveValue Health201013218018719818064
   PubMed Web of Science ®Google Scholar
• WangTCheungKMehtaPRomanSWalkerHSosaJRecombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United StatesJ Clin Endocrinol Metab20109541672168020139234
   PubMed Web of Science ®Google Scholar
• KebebewEDuhQClarkOTotal thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical modelWorld J Surgery20002412951302
   PubMed Web of Science ®Google Scholar
• NICEProcess and Methods Guides: Guide to the Methods of Technology Appraisal2013 Available from: http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdfAccessed May 29, 2015
   Google Scholar
• StajduharKINeithercutJChuEThyroid cancer: patients’ experiences of receiving iodine-131 therapyOncol Nurs Forum20002781213121811013902
   PubMedGoogle Scholar
• SawkaAMGoldsteinDPBrierleyJDThe impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative studyPLoS One200941e419119142227
   PubMed Web of Science ®Google Scholar
• EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• BrazierJUsherwoodTHarperRThomasKDeriving a preference-based single index from the UK SF-36 Health SurveyJ Clin Epidemiol199851111511289817129
   PubMed Web of Science ®Google Scholar
• EisenhauerETherassebPBogaertscJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation ProgramCommon Toxicity Criteria v.2.02009 Available from: http://www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdfAccessed November 18, 2014
   Google Scholar
• TorranceGWThomasWHSackettDLA utility maximization model for evaluation of health care programsHealth Serv Res1972721181335044699
   PubMedGoogle Scholar
• AraRWailooAJNICE Decision Support Unit (DSU)Technical Support Document 12: The Use of Health State Utility Values in Decision Models2011 Available from: http://www.nicedsu.org.uk/TSD12%20Utilities%20in%20modelling%20FINAL.pdfAccessed December 4, 2014
   Google Scholar
• Office for National Statistics (ONS)Census for England and Wales2011 Available from: http://www.ons.gov.uk/census/index.htmlAccessed December 4, 2014
   Google Scholar
• KindPDolanPGudexCWilliamsAVariations in population health status: results from a United Kingdom national questionnaire surveyBMJ19933167367419529408
   PubMed Web of Science ®Google Scholar
• LloydANafeesBNarewskaJDewildeSWatkinsJHealth state utilities for metastatic breast cancerBr J Cancer20069568369016967055
   PubMed Web of Science ®Google Scholar
• NafeesBStaffordMGavrielSBhallaSWatkinsJHealth state utilities for non-small cell lung cancerHealth Qual Life Outcomes200868418939982
   PubMed Web of Science ®Google Scholar
• CooperDSDohertyGMHaugenBRRevised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid2009191167121419860577
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCMJarzabBDECISION InvestigatorsSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet201438431932824768112
   PubMed Web of Science ®Google Scholar
• SwinburnPLloydANathanPChoueiriTKCellaDNearyMPElicitation of health state utilities in metastatic renal cell carcinomaCurr Med Res Opin20102651091109620225993
   PubMed Web of Science ®Google Scholar
• LongworthLRowenDNICE Decision Support Unit (DSU) Support Document 10: The Use of Mapping Methods to Estimate Health State Utility Values2011 Available from: http://www.nicedsu.org.uk/TSD%2010%20mapping%20FINAL.pdfAccessed December 8, 2014
   Google Scholar